Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
Evolent Health, Inc. (NYSE: EVH) announced it will release its 2025 fourth-quarter and year-end financial results on Tuesday, February 24, 2026, after market close, followed by a conference call at 5 p.m. ET. Shareholders and interested participants can access the live broadcast and an audio playback on Evolent's investor relations website. The company specializes in improving health outcomes for people with complex conditions, focusing on making healthcare simpler and more affordable.
Evolent Health to offer $140M in convertible notes, Targets 2025 debt, stock buyback
Evolent Health announced a private offering of $140 million in convertible senior notes due in 2029, with an option for initial purchasers to buy an additional $21 million. The company expects to use the net proceeds to repay its 2025 convertible notes and potentially repurchase shares of its Class A common stock. Additionally, Evolent Health plans to enter into capped call transactions to mitigate potential dilution from the conversion of the notes.
Take Care Before Diving Into The Deep End On Evolent Health, Inc. (NYSE:EVH)
Evolent Health, Inc. (NYSE:EVH) has a low price-to-sales (P/S) ratio of 0.2x, significantly below the Healthcare Services industry average. While analysts forecast comparable revenue growth for Evolent Health against the industry, its recent short-term revenue decline may be contributing to the low P/S ratio. Investors are advised to consider potential unobserved threats and revenue volatility despite the subdued risk of a price drop.
Price-Driven Insight from (EVH) for Rule-Based Strategy
This article from Stock Traders Daily provides a price-driven insight for Evolent Health Inc Class A (NYSE: EVH) using AI models. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The platform offers real-time entry and exit signals, risk-reward ratios, and custom risk management settings.
To recruit its new finance chief, Evolent puts $2.35M in stock on the table
Evolent (NYSE: EVH) announced a one-time inducement restricted stock unit award of 587,500 shares, valued at $2.35 million, to its new Chief Financial Officer, Mario Ramos. This award was granted under NYSE Listing Rule 303A.08 because Ramos was not a prior employee and will vest over three years, contingent on his continued employment. The market reacted positively, with EVH shares gaining 1.54% on the day this news was published.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time restricted stock unit award of 587,500 shares to Mr. Mario Ramos, their new Chief Financial Officer, effective January 2, 2026. This Inducement Award, valued at $2,350,000, is a material inducement for his employment and vests over three years, contingent on his continued employment. The award was granted in accordance with New York Stock Exchange Listing Rule 303A.08.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years and was granted in accordance with NYSE Listing Rule 303A.08, as Mr. Ramos was a new hire. Evolent specializes in health outcomes for complex conditions.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. has granted a one-time restricted stock unit award covering 587,500 shares to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This Inducement Award, valued at $2,350,000, was granted as a material inducement for his employment, adhering to NYSE Listing Rule 303A.08, and vests over three years contingent on continued employment.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years, contingent on continued employment. The grant complies with NYSE Listing Rule 303A.08, as Mr. Ramos was not a previous employee.
Evolent Health (EVH) names new independent director and reiterates Q4 2025 guidance
Evolent Health announced that Cheryl Scott retired from its Board of Directors and Jill Smith was appointed as a new independent director. The company also reaffirmed its fourth-quarter 2025 revenue guidance of $462.0 million to $472.0 million and Adjusted EBITDA guidance of $30.0 million to $40.0 million. This guidance is consistent with its previous outlook from November 6, 2025.
Hopeful Week For Insiders Who Bought US$1.38m Of Evolent Health Stock
Evolent Health (NYSE:EVH) insiders recently bought $1.38 million worth of shares, though their investment is still down by $709k. Despite the losses, their purchases, including a significant one by Co-Founder Seth Blackley at a higher price, indicate a belief in the company's future. Insider ownership stands at 1.8%, valued at $8.1 million.
Evolent (NYSE: EVH) and AON unveil gold-card model removing most prior auth in oncology
Evolent Health (NYSE: EVH) and American Oncology Network (AON) have announced a national partnership to deploy a quality-focused cancer care model that aims to reduce costs, speed treatment, and eliminate prior authorization for providers who meet quality standards. Key elements include "gold-carding" providers, an AI analytics platform called MiBA for personalized treatment insights, and Evolent's Careology navigation program. The model, set to roll out in select markets in the year ahead, seeks to improve clinical decision-making and reward high-quality care.
UnitedHealth (UNH) Receives a Buy from Piper Sandler
Piper Sandler maintained a Buy rating on UnitedHealth (UNH) with a price target of $423.00, while Morgan Stanley also issued a Buy rating. However, TD Cowen maintained a Hold rating on the stock. Insider sentiment for UNH is currently negative, with some insiders selling shares recently.
Evolent Health Q3 2025 Earnings: Revenue Decline Expected - News and Statistics
Evolent Health (NYSE: EVH) is projected to report a 24.8% year-on-year revenue decline to $467.3 million for Q3 2025, with adjusted earnings around $0.11 per share. The company has previously missed revenue expectations, and its stock has dropped 20.6% in the last month, contrasting with some peers in the healthcare technology segment. The average analyst price target is significantly higher than its current share price.
Evolent Health, Inc. Appoints Mario Ramos as Chief Financial Officer, Effective January 1, 2026
Evolent Health, Inc. has announced the appointment of Mario Ramos as its new Chief Financial Officer, effective January 1, 2026. Mr. Ramos brings extensive experience from previous CFO roles at WellBe Senior Medical, Evolv Technology Holdings, Inc., and Edelman Financial Engines, as well as senior positions at CVS Health. His appointment is part of a broader restructuring of leadership roles within the company.
Evolent Announces Third Quarter 2025 Results
Evolent Health, Inc. announced strong financial results for the third quarter of 2025, exceeding expectations for Adjusted EBITDA and revenue. The company secured over $500 million in new annualized revenue set to launch in 2026, bringing its preliminary 2026 revenue forecast to $2.5 billion. Evolent also restructured its leadership team, appointing Mario Ramos as CFO and Katie DiPerna as COO, to support its accelerating growth and enhance financial discipline.
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones - news.stocktradersdaily.com
This article provides a detailed analysis of Evolent Health Inc (EVH) with a focus on AI-generated trading signals and risk zones. It highlights weak sentiment across all time horizons, suggesting a short bias, and presents specific trading strategies (Long, Breakout, Short) with entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels.
Q3 2025 Results Nov. 6 — Evolent to Report Q3 financials, host 5 p.m. ET call and webcast of investor conferences
Evolent (NYSE: EVH) will release its third-quarter 2025 financial results on Thursday, November 6, 2025, after market close, followed by a conference call at 5:00 p.m. ET. The company will also participate in several upcoming investor conferences in November and December 2025. Live audio webcasts and replays of these events will be available on Evolent's investor relations website.
Evolent Health Sells Medicare Primary Care Business Serving 120K Members for $113M
Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. This strategic divestiture, involving operations serving over 120,000 members and 1,000+ physicians, aims to improve annual cash flow by over $7 million and focuses Evolent on its core specialty business. The company also reaffirmed its Q3 and full-year 2025 financial guidance, excluding the transaction's impact.
Cormedix (CRMD) Gets a Buy from Truist Financial
Truist Financial analyst Jailendra Singh has maintained a Buy rating on Cormedix (CRMD), with the company's shares closing recently at $13.70. Singh has an average return of -10.9% and a 35.82% success rate, specializing in the Healthcare sector. The analyst consensus for Cormedix is currently a Strong Buy, with an average price target of $19.33.
Evolent Health prices convertible notes offering
This article states that Evolent Health has priced a convertible notes offering. No further details are available in the provided content.
Evolent prices $145 million convertible notes offering at 4.50%
Evolent Health, Inc. announced the pricing of $145 million in 4.50% convertible senior notes due 2031, an increase from the previously planned $140 million offering. The company plans to use the proceeds to repurchase existing 2025 convertible notes and Class A common stock. This financial maneuver is expected to reduce annual interest expenses.
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. announced a proposed offering of $140.0 million in convertible senior notes due 2031. The company intends to use the proceeds to repurchase a portion of its existing 1.50% convertible senior notes due 2025 and approximately $40.0 million of its Class A common stock. This strategic financial move aims to manage existing debt and optimize its capital structure.
$140M Debt Offering: Evolent Health Launches Convertible Notes to Refinance Debt and Buy Back Stock
Evolent Health announced a proposed offering of $140.0 million in convertible senior notes due 2031, with an option for an additional $20.0 million. The company plans to use $100.0 million of the proceeds to repurchase existing 1.50% convertible senior notes due 2025 and $40.0 million to repurchase Class A common stock. This move is aimed at refinancing debt and returning capital to shareholders, extending debt maturities from 2025 to 2031.
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Evolent Health, Inc. has nominated Shawn Guertin, former CFO of CVS Health, Aetna, and Coventry Health Care, to its Board of Directors. Guertin's nomination is part of Evolent's ongoing board refreshment efforts and aims to leverage his extensive experience in driving growth and profitability within the healthcare industry. He is expected to be elected at the annual stockholders meeting on June 5, 2025, taking the seat of the retiring Diane Holder.
Evolent Health, Inc. SEC 10-K Report
Evolent Health, Inc. has released its annual 10-K report, highlighting significant financial growth with a 30.1% increase in total revenue to $2,554.7 million, driven by expanding specialty care management services and strategic acquisitions. The company reported a net loss of $(93.5) million, an improvement from the previous year, and detailed its focus on value-based care, integrated technology, and strategic partnerships despite facing challenges like reliance on a limited number of partners and regulatory risks. Future plans include continued expansion through organic growth and acquisitions, while proactively managing medical costs and navigating a complex regulatory environment.
Evolent Announces Fourth Quarter and Full Year 2024 Results
Evolent Health, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported revenue of $646.5 million for Q4 2024 and $2,554.7 million for the full year 2024, representing significant growth over the previous year. Evolent also secured contract amendments expected to yield a $115 million annual improvement for 2025 and maintained 100% partner contract retention across its top customers.
Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms
Evolent Health Inc (NYSE: EVH) is reportedly exploring a sale after receiving takeover inquiries from private equity firms and healthcare providers, including TPG Inc, Clayton, Dubilier & Rice, and KKR & Co. Inc. Health insurer Elevance Health Inc (NYSE: ELV) has also shown interest and may partner with a private equity firm for a deal. Despite a 38% revenue increase in its latest quarter, the company faces financial challenges due to lower billing rates from payer customers.
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Evolent Health, Inc. announced the pricing of $350.0 million in 3.50% convertible senior notes due 2029, with an option for initial purchasers to buy an additional $52.5 million. The company intends to use the net proceeds, along with available liquidity, to prepay a portion of its outstanding term loan facility. The notes are convertible into cash, Class A common stock, or a combination, at an initial conversion price of approximately $38.00 per share, representing a 42.50% premium over the closing price on December 5, 2023.
Form 424B7 Evolent Health, Inc.
Evolent Health, Inc. filed a Form 424B7 prospectus supplement for the resale of up to 8,474,576 shares of its Class A common stock by identified selling stockholders. The company will not receive any proceeds from these sales, which may occur through various methods including underwriters, brokers, or direct transactions. Investing in EVH Class A common stock involves risks, and the last reported closing price on November 2, 2023, was $24.01 per share.
Upmc Cuts Stake in Evolent Health (EVH)
Upmc has reduced its stake in Evolent Health (EVH), decreasing its ownership from 8.60% to 5.84%. Despite this, analyst forecasts predict a 38.90% upside for the stock, with projected annual revenue increasing by 39.17%. Institutional ownership of EVH has also seen a recent increase, with several large shareholders adjusting their positions.
EVOLENT HEALTH TO ACQUIRE IPG
Evolent Health announced its definitive agreement to acquire IPG, a surgical management solutions company for musculoskeletal conditions, for $375 million plus up to $87 million in contingent consideration. This acquisition aims to expand Evolent's value-based specialty care solutions, add new customers, and improve its financial profile by being immediately accretive to Adjusted EBITDA margins and cash flow. The transaction is expected to close in Q3 2022 and will diversify Evolent's customer and revenue mix.
Evolent Health stock spikes following report of potential sale to Walgreens
Evolent Health's stock saw a spike following a report suggesting a potential sale to Walgreens. This news comes less than two months after Evolent Health itself acquired another company. The article notes Evolent Health went public in 2015.
Evolent Health Announces Cooperation Agreement With Engaged Capital
Evolent Health has entered into a Cooperation Agreement with Engaged Capital, appointing Craig Barbarosh to its Board of Directors and forming a Strategy Committee focused on value creation. The company will also seek stockholder approval to declassify its Board at the 2021 annual meeting, moving towards one-year terms for directors. This agreement aims to drive profitable growth and maximize shareholder value through strategic corporate changes.
Activist sets sights on another health-care company with break-up potential
Activist investor Engaged Capital has targeted Evolent Health Inc. (EVH), acquiring a 9.99% stake with the aim of unlocking intrinsic value. Engaged Capital intends to push Evolent Health to divest its underperforming True Health segment and focus on its profitable services business. This strategy could lead to a sale of the entire company, with Engaged Capital prepared to nominate directors if constructive engagement fails.
CEO of Passport Health's parent company to step down
Frank Williams, the CEO of Evolent Health, the parent company of Passport Health, is set to step down from his role in October 2020. A fellow co-founder will assume the CEO position. This news comes as Passport Health Plan recently sold to a rival company.
Evolent Health CEO to step down
Frank Williams, CEO and co-founder of Evolent Health, is scheduled to step down from his position in October. Another co-founder will assume the CEO role. This news comes amidst previous reports of Evolent Health's subsidiary sales and acquisitions.
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolent Health, Inc. (EVH)
Glancy Prongay & Murray LLP (GPM) is reminding investors of a looming October 7, 2019 deadline to file a lead plaintiff motion in a class action lawsuit against Evolent Health, Inc. (NYSE: EVH). The lawsuit concerns investors who purchased Evolent common stock between March 3, 2017, and May 28, 2019, alleging that Evolent made materially false and misleading statements regarding its business and acquisition of Passport Health Plan. Evolent's stock fell nearly 30% after announcing the acquisition, which contradicted previous statements about the company's strategic focus.
Evolent Health is being sued over $70M Passport acquisition
Evolent Health LLC is facing a lawsuit from a shareholder alleging that its $70 million acquisition of a majority stake in Passport Health Plan is fraudulent. The suit was filed in a Virginia federal court. The acquisition deal had previously sparked other related legal and partnership discussions for Passport Health Plan.
$23.5M settlement reached in suit over acquisition of Louisville's Passport Health Plan
A $23.5 million settlement was approved in November 2022 in a class-action lawsuit filed against Evolent Health regarding its acquisition of Louisville's Passport Health Plan. The lawsuit, filed by Saxena White P.A., alleged that Evolent Health and its executives made false and misleading statements to investors about the acquisition of the financially struggling Passport. The settlement applies to individuals and entities who purchased or acquired Evolent Health stock between January 10, 2018, and May 28, 2019.
Evolent Health stock falls on bigger loss, new stock offering
Arlington-based Evolent Health is planning a public offering of its Class A common stock to raise $175 million, as announced in its second-quarter earnings report. The company's stock fell following this news and a bigger loss reported the same day. This offering comes amidst a strategic move to secure additional capital.
Evolent Health, Inc. Announces Pricing of $110.0 Million of Convertible Senior Notes Due 2021
Evolent Health, Inc. announced the pricing of $110.0 million aggregate principal amount of 2.00% convertible senior notes due 2021, offered to qualified institutional buyers. The notes are convertible into shares of Evolent Health's Class A common stock at an initial conversion price of approximately $24.03 per share, representing a 27.50% premium over the closing price on November 29, 2016. The net proceeds are intended for working capital and general corporate purposes of Evolent Health LLC, with settlement expected on December 5, 2016.
Evolent Health to acquire Chicago competitor for $145 million
Arlington-based Evolent Health announced its acquisition of Chicago company Valence Health Inc. for $145 million. The news was met positively by Wall Street. This acquisition is a significant move for Evolent Health.
Passport Health Plan and Evolent Health form Strategic Alliance to create Medicaid Center of Excellence in Louisville
Passport Health Plan and Evolent Health have announced a strategic alliance to create the Medicaid Center of Excellence in Louisville, Kentucky. This first-of-its-kind initiative combines Passport's Medicaid managed care expertise with Evolent's technology and operations to offer centralized services for provider-led Medicaid health plans nationwide. The alliance aims to improve patient health outcomes, lower costs, create jobs, and further establish Louisville as a healthcare innovation hub.
Evolent Health Inc. (EVH) Is Rising On First Day - IPO Alert
Evolent Health Inc. (EVH) began trading on its first day after pricing its initial public offering of 11,500,000 shares of Class A common stock at $17.00 per share. The stock is currently up 0.66 at $17.66 with 3.6 million shares traded.
